 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial (Lomond Auditorium) - Sep 24, 2024 - Abstract #EANO2024EANO_431;
Three patients responded to the treatment. A complete response and long-term survival occurred in two of them.
- || recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
Trial completion: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - Feb 16, 2024
P1, N=15, Completed, Sponsor: Stemgen
A complete response and long-term survival occurred in two of them. Active, not recruiting --> Completed
- || recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
Enrollment closed, Trial completion date, Trial primary completion date: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - Nov 19, 2020
P1, N=15, Active, not recruiting, Sponsor: Stemgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Mar 2021 | Trial primary completion date: Jan 2019 --> Oct 2020
- | recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
Trial completion date, Trial primary completion date: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - Nov 7, 2018
P1, N=15, Recruiting, Sponsor: Stemgen
Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Mar 2021 | Trial primary completion date: Jan 2019 --> Oct 2020 Trial completion date: Sep 2018 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Jan 2019
- recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
Enrollment open, Trial initiation date, Trial primary completion date: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - Oct 6, 2017
P1, N=15, Recruiting, Sponsor: Stemgen
Trial completion date: Sep 2018 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Jan 2019 Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Jul 2017 | Trial primary completion date: Oct 2017 --> Jun 2018
- | recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
New P1 trial: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov) - Aug 15, 2016
P1, N=15, Not yet recruiting, Sponsor: Stemgen